These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15583726)

  • 1. Admission troponin T, advanced age and male gender identify patients with improved myocardial tissue perfusion after abciximab administration for ST-segment elevation myocardial infarction.
    Lehrke S; Giannitsis E; Katus HA
    Thromb Haemost; 2004 Dec; 92(6):1214-20. PubMed ID: 15583726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
    Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
    Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
    Xu Q; Yin J; Si LY
    Int J Cardiol; 2013 Jan; 162(3):210-9. PubMed ID: 22769575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
    Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction.
    Wijnbergen I; Tijssen J; van 't Veer M; Michels R; Pijls NH
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):379-84. PubMed ID: 23553888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.
    Perkan A; Vitrella G; Barbati G; De Monte A; D'Agata B; Merlo M; Giannini F; Della Grazia E; Rakar S; Salvi A; Igidbashian D; Morgera T; Zalukar W; Sinagra G
    J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):127-35. PubMed ID: 22343257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Estévez-Loureiro R; Salgado-Fernández J; Marzoa-Rivas R; Barge-Caballero E; Pérez-Pérez A; Noriega-Concepción V; Calviño-Santos R; Vázquez-Rodríguez JM; Vázquez-González N; Castro-Beiras A; Kaski JC
    Thromb Res; 2009 Nov; 124(5):536-40. PubMed ID: 19467699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of abciximab as adjunctive therapy in primary percutaneous coronary intervention patients (results from the DANAMI-2 trial).
    Sejersten M; Maynard C; Clemmensen P;
    Acute Card Care; 2006; 8(2):75-82. PubMed ID: 16885070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry).
    Dziewierz A; Mielecki W; Siudak Z; Rakowski T; Janzon M; Birkemeyer R; Zasada W; Dubiel JS; Dudek D
    Atherosclerosis; 2012 Jul; 223(1):212-8. PubMed ID: 22658254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
    Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
    J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.
    Admiral Investigators
    Eur Heart J; 2005 Dec; 26(23):2520-3. PubMed ID: 16249219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.